News

Initial data from a feasibility study conducted with Apple devices and digital apps has shown the potential for these to be able to differentiate people with mild cognitive impairment and mild Alzheimer disease dementia.

Exposure to the care of either a neurologist or comprehensive epilepsy program epileptologist resulted in a significantly lower rate of premature mortality than that of those who were not, based on findings from a cohort of more than 20,000 cases.

The associate professor of neurology and medical director of the epilepsy monitoring unit and Penn epilepsy surgical program at the University of Pennsylvania discussed the findings of a single-center review of off-label clobazam use for patients with drug-refractory epilepsy.

The new drug application for Libervant is expected to be completed in the fourth quarter of 2019, which if approved, would offer a potentially first in class oral treatment for breakthrough or cluster seizures.

The associate professor of neurology and medical director of the epilepsy monitoring unit and Penn epilepsy surgical program at the University of Pennsylvania shared insight into the prioritization of women with epilepsy who may intend to get pregnant.

New study findings confirm that idiopathic rapid‐eye‐movements sleep behavior disorder and RBD secondary to narcolepsy type 1 can be identified via video‐polysomnography and skin biopsy for phosphorylated α‐synuclein deposits.

The Rare Disease Cures Accelerator-Data and Analytics Platform, aimed at accelerating the development of new therapies, will launch at a joint meeting between the Critical Path Institute and the National Organization for Rare Disorders on Tuesday, September 17 in Bethesda, Maryland.

The attending neurologist at the Montefiore Headache Center and assistant professor of neurology at the Albert Einstein College of Medicine spoke about preventive treament for perimenstrual-related migraine.

Six-month results show significant improvements in motor symptoms, mentation, behavior, and mood, with a prolonged residual benefit.

The director of multiple sclerosis neuropsychiatry at Brigham and Women’s Hospital discussed how a collaborative approach can help to address mental health disorders in patients with multiple sclerosis.

The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in the armamentarium, and how therapies like eptinezumab can improve patients’ belief in their physician’s ability to help.

The agency said the gene therapy should remain on the market while it assesses the situation and does not impact their evaluation of data from the human clinical trials.

Subjects receiving GRF6019 maintained cognitive and functional status over a period of 6 months, and dosing was reported to be safe and well-tolerated.

Dysphagia is a common symptom and complication of neurologic disorders, yet no clear treatment protocol has been identified.

The CEO and co-founder of Theranica discussed the migraine treatment device’s mechanism of action and its successes in reducing medication overuse headache.

The professor of neurology at University Medical Center Schleswig‐Holstein, and member of the department of neurodegenerative diseases at University Hospital Tübingen shared insight into the quantitative gait characteristics measured by wearable devices which can play an important role in the identification of prodromal Parkinson disease and its progression.

The findings demonstrated that the galcanezumab group—made up of those with both chronic and episodic migraine—experienced a 4.1-day reduction in monthly migraine headache days compared to a 1.0-day reduction with placebo.

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne detailed how the transition from states of illness to wellness after epilepsy surgery can result not just in brain changes, but psychosocial challenges for patients.

Mind Moments® a podcast from NeurologyLive®, brings you exclusive interviews with experts in neurologic disorders.

The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.

Interim data from the first 8 pediatric patients showed that the AAV-CLN6 gene therapy demonstrated a positive impact on motor and language function compared to a natural history dataset, as well as in comparison to in-study sibling pairs.

Neurology News Network for the week ending August 3, 2019.

The director of the Pediatric Stroke Program at CHOP spoke about the need to improve early recognition of pediatric stroke and physician awareness of the condition, which many believe is underdiagnosed and underestimated.

The professor of neurology and founding chair of the John T. Macdonald Foundation Department of Human Genetics at the University of Miami discussed the distinctions between Alzheimer disease risk of ethnicities that share genetic markers.

The program director of neurology at the Zucker School of Medicine, Northwell Health, spoke about the great advances of the new CGRP medications available for the prevention of migraine.

The clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne spoke about what physicians need to provide to help patients through the adjustment period after epilepsy surgery.

Patients who received diroximel fumarate experienced statistically significantly fewer number of days of key gastrointestinal symptoms with intensity scores ≥2 on the IGISIS compared to those on dimethyl fumarate.

The FDA has assigned the application a PDUFA target action date of March 17, 2020.